Company

A functioning liver is essential for human life.  The HEPATIQ test measures liver function which deteriorates with chronic liver disease (CLD).  The residual function is important for therapeutic planning and predicting adverse outcomes many of which are related to decrease in hepatic function.  Loss of function may necessitate liver transplantation.  Other products measure fibrosis which is not good enough.  Function measurements allow identification of patients at risk for future decompensation (inability to compensate for loss of liver function), and patients with adequate hepatic reserve who would have benign outcomes.

The HEPATIQ software uses nuclear medicine images taken from any SPECT scanner using the Quantitative Liver-Spleen Scan (QLSS) protocol.  The patient is injected with the standard Technician-99 sulfur colloid radioisotope and planar and SPECT images acquired.  The images are analyzed to calculate indices of liver function (PHM), spleen volume (fSV) and liver volume (fLV).  These three indices are used to generate a suggested impression. A one-page HEPATIQ report is prepared for clinical use.

Numerous papers have been published on QLSS, PHM, fSV and fLV.  Two of the most important clinical trials, HALT-C and A2ALL, were prospective trials sponsored by the NIH and performed at prestigious academic institutions.  The HALT-C showed that PHM and fSV predict clinical outcomes and out-perform any combination of blood tests and biopsies.  The A2ALL showed the value of PHM and fLV in serial measurements during liver regeneration.

The HEPATIQ software is protected by an issued patent and six registered trademarks.  HEPATIQ has been cleared by the FDA for sale.  The company is also in compliance with U.S. Quality System Regulations.  Competitive approaches to assessing chronic liver disease are: (1) blood tests, (2) elastography, (3) liver biopsy, and combinations thereof.  These have many disadvantages. HEPATIQ is superior to all of them because it precisely measures hepatic function.

Customers for HEPATIQ are medical centers.  They will buy because: (1) HEPATIQ will increase their revenues and (2) because their clinicians will demand the HEPATIQ test to better manage liver disease patients.  Our customers make on average $1,200 in extra revenue every time they perform a HEPATIQ test.

The company has completed product development, obtained regulatory approvals, secured patents and trademarks, and has paying customers.